GRI Bio's "Why Now" Video: The Data Is Real, the Funding Isn't

GRI Bio told investors Thursday that it is "featured" in a "Why Now" on-demand video webcast, the company's term for a sponsored video in which chief executive Marc Hertz makes the case for GRI-0621, its once-daily pill for idiopathic pulmonary fibrosis. The timing is deliberate: the full Phase 2a dataset goes on stage at the European Respiratory Society's Barcelona congress, September 5–9.

Here is the part the press release doesn't say in the same breath. The stock being pitched trades at about $1.90, values the entire company at roughly $4 million, and has lost more than 90% of its value over the past year. Quote data puts the 52-week range at $1.36 to $80.36, with the top printed during the froth around January's 1-for-28 reverse stock split.

"Why now" is the right question. It's just a funding question, not the question the video is built to answer.

The data is the good part

IPF earns a moment of context: it is a progressive, ultimately fatal scarring of the lungs, and treatment remains limited to two approved drugs that come with significant side effects and poor patient compliance. A therapy with a better tolerability profile has a real opening.

GRI-0621's Phase 2a readout backs that up. In 35 patients treated for 12 weeks, 80% of them already on standard antifibrotic therapy, the drug met its primary safety endpoint with no drug-related severe or serious events. The tolerability numbers are what stand out: zero cough versus 25% on placebo, and diarrhea in 13% of treated patients versus 33% on placebo — despite the active arm carrying 67% more nintedanib, the approved antifibrotic most notorious for gut trouble. On lung function, the drug showed a placebo-adjusted gain of about 99 mL in forced vital capacity — a measure of how much air a patient can force out, which IPF patients normally lose month by month — and 139 mL in the subset also taking standard of care; 80% of placebo patients lost lung function over 12 weeks, versus 39% of treated patients that gained. Collagen-remodeling biomarkers flipped from fibrogenic to fibrolytic, the fingerprint of tissue repair rather than further scarring. Orphan drug designation in June gives the drug seven years of U.S. market exclusivity if it ever reaches market.

None of this is a powered efficacy claim. Phase 2a is a 35-patient safety trial, and the lung-function numbers are exploratory. But the direction is coherent, and the profile of "adds on top of nintedanib without making GI side effects worse" is a genuine product wedge in a disease whose standard of care all too often stops patients from staying on it.

The market has been mathing this all year

The market's verdict, though, has been consistent: sell the news. The day after the December topline, GRI priced an $8 million public offering, and the stock slumped roughly 20% in the aftermath. Investors have watched the pattern repeat, because the pattern is the point.

Two reverse stock splits in twelve months tell the story. A 1-for-17 split came in February 2025, and a 1-for-28 in January 2026, each engineered to keep the share price above Nasdaq's $1 minimum. For a beginner, a reverse split is arithmetic theater — 28 shares become one and the price multiplies by 28, so nothing of value changes by itself. The erosion comes from what follows: an at-the-market facility that sold $6.8 million of new shares in the first quarter alone, and a $250 million shelf registration filed in late January. Good news keeps arriving, and new shares keep arriving with it. The analyst consensus that quotes a "Strong Buy" and an $18.50 target is a two-analyst label on an illiquid microcap — sentiment, not evidence.

The forward math is what "why now" can't fix

The company had $10.9 million of cash at June 30 and has been burning roughly $1.6 to $2 million per quarter. Management's own guidance funds operations into the second quarter of 2027 — planning work, not drug development. GRI Bio has said outright that substantial additional capital will be required to fund future clinical trials, and an IPF Phase 2b will cost multiples of the entire $4 million market cap. There are two ways to pay for it: current holders, through the shelf and the ATM, or an outsider, through a licensing deal. One of those is dilution; the other is the actual news.

At $4 million, the market is capitalizing roughly nothing for seven years of IPF exclusivity behind a differentiated early readout. That is the profile of an undervalued option, and it is also exactly what a dilution machine looks like. The two are separated by a single event: who writes the Phase 2b check. The ERS presentation on September 5–9 tells you whether the signal holds up in the disclosed detail; the next financing announcement tells you whether the discount was a mispricing or the truth. The "Why Now" video is best read as data on the company's need for capital — the one variable in this story that has only gone up.